Glenmark Pharmaceuticals is currently trading at Rs. 516.85, up by 0.85 points or 0.16% from its previous closing of Rs. 516.00 on the BSE.
Glenmark Pharmaceuticals The scrip opened at Rs. 513.50 and has touched a high and low of Rs. 519.10 and Rs. 505.00 respectively. So far 40875 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 690.60 on 19-Jul-2021 and a 52 week low of Rs. 442.15 on 25-Mar-2021.
Last one week high and low of the scrip stood at Rs. 528.05 and Rs. 508.20 respectively. The current market cap of the company is Rs. 14557.06 crore.
Glenmark Pharmaceuticals The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 34.96% and 18.40% respectively.
Glenmark Pharmaceuticals’ subsidiary — Glenmark Pharmaceuticals Inc., USA (Glenmark) has received tentative approval by United States Food & Drug Administration (USFDA) for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL) Single-Dose Pre-Filled Syringe, the generic version of Lexiscan Injection, 0.4 mg/5 mL (0.08 mg/mL), of Astellas US, Inc. Sales data for the 12 month period ending November 2021, the Lexiscan Injection, 0.4 mg/5 mL (0.08 mg/mL) market achieved annual sales of approximately $659.9 million.
Glenmark’s current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 47 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.